Items where authors include "Hanna, G."

Article

Fennell, D.A., Kirkpatrick, E., Cozens, K. et al. (13 more authors) (2018) CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. 233. ISSN 1745-6215

Proceedings Paper

Haslett, K., Ashcroft, L., Bayman, N. et al. (11 more authors) (2018) PO-0752: Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S387-S387.

Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.

Haslett, K., Bayman, N., Franks, K. et al. (11 more authors) (2017) MA 09.11 Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) – a feasibility study. In: Journal of Thoracic Oncology. IASLC 18th World Conference on Lung Cancer, 15-18 Oct 2017, Yokohama, Japan. Elsevier , S1838-S1839.

Hanna, G., McDonald, F., Greystoke, A. et al. (7 more authors) (2017) EP-1228 : UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC. In: Radiotherapy and Oncology. ESTRO 36 - European Society for Radiotherapy & Oncology, 05-09 May 2017, Vienna, Austria. Elsevier , S662-S663.